Shares of Cerulean Pharma Inc. (NASDAQ:CERU) fell 0.7% during mid-day trading on Monday . The stock traded as low as $2.80 and last traded at $2.97, with a volume of 140,462 shares trading hands. The stock had previously closed at $2.99.

Several research firms recently issued reports on CERU. Leerink Swann reissued a “buy” rating on shares of Cerulean Pharma in a research report on Sunday, June 26th. Canaccord Genuity reaffirmed a “buy” rating on shares of Cerulean Pharma in a report on Tuesday, May 3rd. Wedbush reaffirmed an “outperform” rating and set a $9.00 price objective on shares of Cerulean Pharma in a report on Tuesday, April 19th. Janney Montgomery Scott assumed coverage on shares of Cerulean Pharma in a report on Wednesday, June 1st. They set a “buy” rating on the stock. Finally, Zacks Investment Research downgraded shares of Cerulean Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, August 10th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $9.25.

The company has a 50 day moving average price of $2.57 and a 200-day moving average price of $2.53. The firm’s market cap is $78.87 million.

Cerulean Pharma (NASDAQ:CERU) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.08. On average, equities analysts predict that Cerulean Pharma Inc. will post ($1.64) earnings per share for the current fiscal year.

Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.